During this week’s 14th Congress of the European Crohn’s and Colitis Organisation, multiple research teams reported on efforts to better understand the factors that impact adalimumab therapy in patients with inflammatory bowel disease (IBD).
During this week’s 14th Congress of the European Crohn’s and Colitis Organisation, multiple research teams reported on efforts to better understand the factors that impact adalimumab therapy in patients with inflammatory bowel disease (IBD).
Early Adalimumab May Be Best for CD
First, investigators who conducted a large retrospective study of patients with Crohn disease (CD) reported on their attempt to evaluate primary nonresponse (PNR) to adalimumab, treatment persistence, and any factors that may be associated with PNR and persistence.
The study included 405 patients with CD who were treated between 2012 and 2017 at 3 centers in France. All patients received full adalimumab induction. In total, 34% had previously received infliximab, and had discontinued because of PNR, loss of response, intolerance, or other reasons.
Median time receiving adalimumab was 1.7 years (interquartile range, 0.7-3.6). In total, 9% of patients had PNR, while 91% maintained scheduled treatment. Drug survival rates for adalimumab 76% at 12 months, 59% at 24 months, and 51% at 36 months.
Two independent predictors of adalimumab failure were identified in a multivariate Cox regression: disease duration of 2 years or more (hazard ratio [HR], 3.16; 95% CI, 1.15-1.85; P = .02) and previous infliximab therapy (HR, 2.38; 95% CI, 1.09-2.57; P = .017).
“Patients with early CD, naive of [anti—tumor necrosis factor] treatments exhibited the best profile to response to adalimumab treatment. Awaiting results from disease modifications trials, these results suggest the clear benefit of introducing biologics early in the disease history,” concluded the authors.
High BMI Does Not Impact Response to Adalimumab
High body mass index (BMI) has been linked with poorer response to biologic therapy in patients with a variety of autoimmune diseases, but data related to the impact of high BMI on non—weight-based therapies, such as adalimumab, have been conflicting. However, researchers from a single center in Greece found that BMI does not impact treatment response to adalimumab in patients with moderately active CD.2
The study included 49 patients who were followed over a period of 2 years. The primary end point of the study was clinical, biological, and endoscopic remission at 24 weeks after initiating adalimumab at a dose of 40 mg every 2 weeks after induction. The mean BMI among patients was 27.13 (range, 19-41).
In total, 67.3% of patients achieved clinical and biological remission, and 59.1% achieved mucosal healing. Patients classified as having obesity, or a BMI over 30, had similar rates of remission as patients without obesity.
“We did not observe any correlation of any BMI cut-off value with clinical, biological, and endoscopic remission,” write the authors.
No Link Between High Serum Levels and Adverse Events
Finally, a research team reported on a study that sought to determine whether high serum adalimumab concentration increases the risk of adverse events (AEs) in patients with IBD.3
The retrospective study included 133 patients with IBD who had at least 1 measurement of serum adalimumab available. The cohort was divided according to the median adalimumab level, 9.8 μg/ml.
In total, 27 AEs were reported. In the 66 patients with higher adalimumab levels, 17 AEs were reported. In the 67 patients with lower adalimumab levels, 10 AEs were reported. The difference between groups was significant, and stratification of the patients into tertiles by adalimumab levels did not show any difference in the rates of AEs among groups, either.
The authors concluded that there does not appear to be an increased risk of AEs for patients with IBD who have higher serum levels of adalimumab.
References
1. Fumery M, Duveau N, Perignon C, et al. Prognostic factors for long-term adalimumab treatment. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P323. ecco-ibd.eu/publications/congress-abstract-s/abstracts-2019/item/p323-prognostic-factors-for-long-term-adalimumab-treatment.html.
2. Soufleris K, Fasoulas K, Kafalis N, Lazaraki G, Tzilves D. Body mass has no effect on treatment response in Crohn’s disease patients with moderate disease activity who receive adalimumab. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P329. ecco-ibd.eu/publications/congress-abstract-s/item/p392-body-mass-index-has-no-effect-on-treatment-response-in-crohn-0039-s-disease-patients-with-moderate-disease-activity-who-receive-adalimumab.html.
3. Narula N, Lauzon B, Marchall J. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P607. ecco-ibd.eu/publications/congress-abstract-s/item/p607-higher-adalimumab-serum-levels-do-not-increase-the-risk-of-adverse-events-in-patients-with-inflammatory-bowel-disease.html.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.